Trials / Terminated
TerminatedNCT00234442
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer
A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iressa (Gefitinib) |
Timeline
- Start date
- 2004-07-01
- Completion
- 2006-02-01
- First posted
- 2005-10-07
- Last updated
- 2009-06-30
Locations
4 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00234442. Inclusion in this directory is not an endorsement.